Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efavirenz + fenofibric acid
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Efavirenz + fenofibric acid is a combination of two distinct pharmaceuticals: **efavirenz**, a non-nucleoside reverse transcriptase inhibitor (NNRTI) primarily used as antiretroviral therapy for HIV/AIDS, and **fenofibric acid**, a lipid-lowering agent classified as a fibrate, indicated for the treatment of mixed dyslipidemia. **Efavirenz** acts by blocking the activity of reverse transcriptase, an enzyme critical for HIV replication, while **fenofibric acid** activates peroxisome proliferator-activated receptor alpha (PPAR-α), leading to reduced triglycerides and increased HDL cholesterol[3][2]. No fixed-dose combination or clinical evidence of joint use for a specific disease is documented; both drugs are approved as monotherapies and for use in combination with other agents within their respective therapeutic classes[3][2]. There is no known marketed product combining both agents.
- Brand names
- Sustiva (efavirenz)TriLipix (fenofibric acid)
- Other names
- EFV (efavirenz)fenofibric acid
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasePPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on efavirenz + fenofibric acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efavirenz + fenofibric acid.